ArticleAntimicrobial agents and chemotherapy2011
Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03193749 (A Trial Testing Amiodarone in Chagas Cardiomyopathy), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH)
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Drug Repurposing in Parasitology: New Uses for Old Drugs to Be Used Through the Host-Parasite Interface.Pathogens (Basel, Switzerland) · 2026Review
- Transcriptomic and ultrastructural responses to Amiodarone-Itraconazole in naturally benznidazole-resistant and -susceptible Trypanosoma cruzi strains.PLoS neglected tropical diseases · 2026Article
- Chagas disease and amiodarone: a bibliometric and systematic review from cell to patient.Frontiers in pharmacology · 2026Review
- Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities.Frontiers in pharmacology · 2023Review
- Editorial: Chagas disease novel drug targets and treatments.Frontiers in cellular and infection microbiology · 2023Article
- Effects of amiodarone, amioder, and dronedarone on Trichomonas vaginalis.Parasitology research · 2022Article
- The Use of AlphaFold forFrontiers in cellular and infection microbiology · 2022Article
- Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage inFrontiers in cellular and infection microbiology · 2022Article
- Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy.Heart rhythm O2 · 2021Article
- Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target AgainstFrontiers in cellular and infection microbiology · 2020Review
- A Combination of Itraconazole and Amiodarone Is Highly Effective againstThe American journal of tropical medicine and hygiene · 2019Article
- Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.BMC infectious diseases · 2017Article
- Epidemiology of Chagas disease in Europe: many calculations, little knowledge.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Review
- The emerging role of amiodarone and dronedarone in Chagas disease.Nature reviews. Cardiology · 2012Review
- In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.Antimicrobial agents and chemotherapy · 2012Article
- In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.Antimicrobial agents and chemotherapy · 2012Article
- Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction.Frontiers in immunology · 2012Article
- Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype.Biochemical pharmacology · 2011Article
- Gap junctions and chagas disease.Advances in parasitology · 2011Review
- Chagas heart disease: report on recent developments.Cardiology in reviewReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the results of the first detailed study of the antiproliferative and ultrastructural effects of amiodarone on Trypanosoma cruzi, the causative agent of Chagas' disease. Moreover, we report the effects of this compound on the recovery of F-actin fibrils, connexin43, and contractility in T. cruzi-infected cardiac myocytes. Amiodarone is the most prescribed class III antiarrhythmic agent and is frequently used for the symptomatic treatment of Chagas' disease patients with cardiac compromise. In addition, recent studies identified its antifungal and antiprotozoal activities, which take place through Ca(2+) homeostasis disruption and ergosterol biosynthesis blockade. We tested different concentrations of amiodarone (2.5 to 10 μM) on infected primary cultures of heart muscle cells and observed a dose- and time-dependent effect on growth of the clinically relevant intracellular amastigote form of T. cruzi. Ultrastructural analyses revealed that amiodarone had a profound effect on intracellular amastigotes, including mitochondrial swelling and disorganization of reservosomes and the kinetoplast and a blockade of amastigote-trypomastigote differentiation. Amiodarone showed no toxic effects on host cells, which recovered their F-actin fibrillar organization, connexin43 distribution, and spontaneous contractility concomitant with the drug-induced eradication of the intracellular parasites. Amiodarone is, therefore, a promising compound for the development of new drugs against T. cruzi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.